Reversible tripeptide thrombin inhibitors as adjunctive agents to coronary thrombolysis: A comparison with heparin in a canine model of coronary artery thrombosis

Journal of Cardiovascular Pharmacology

Volumn 21, Issue 4, 1993, Pages 587-594

  Jackson, Charles V ^a   Wilson, Harve C ^a   Gail Growe, V ^a   Shuman, Robert T ^a   Gesellchen, Paul D ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Adjunct; Heparin; LY294468; Rethrombosis; Thrombin; Thrombolysis

Indexed keywords

ALTEPLASE; EFEGATRAN; HEMOGLOBIN; HEPARIN; LY 178207; TERT BUTOXYCARBONYL DEXTRO PHENYLALANYLPROLYLARGINAL; THROMBIN; THROMBIN INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; BLEEDING; BLEEDING TIME; BLOOD CLOT LYSIS; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY THROMBOSIS; DOG; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART RATE; HEMATOCRIT; HEMODYNAMICS; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOGENESIS;

ANIMAL; ANTITHROMBINS; BLEEDING TIME; COMPARATIVE STUDY; CORONARY THROMBOSIS; DISEASE MODELS, ANIMAL; DOGS; FEMALE; HEMODYNAMICS; HEPARIN; OLIGOPEPTIDES; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0027407160     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/00005344-199304000-00012     Document Type: Article

References (34)

1. William DO, Borer J, Braunwald E, et al. Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction: a report from the NHLBI thrombolysis in myocardial infarction trial. Circulation 1986; 73:338-46.
2. Golino P, Willerson JT. Is thrombolysis alone the best therapy for acute myocardial infarction? Tex Heart Institute J 1991;18:50-61.
3. Shebuski RJ, Smith JM, Storer BL, Granett JR, Bugelski PJ. Influence of selective endoperoxide/thromboxane A2 receptor antagonism with sulotroban on lysis time and reocclusion rate after tissue plasminogen activator-induced coronary thrombolysis in the dog. J Pharmacol Exp Ther 1988;246: 790-6.
4. Fitzgerald DJ, FitzGerald GA. Role of thrombin and throm-boxane A2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator. Proc Natl Acad Sci USA 1989;86:7585-9.
5. Schumacher WA, Heran CL. Effect of thromboxane antagonism on recanalization during streptokinase-induced thrombolysis in anesthetized monkeys. J Cardiovasc Pharmacol 1989;13:853-61.
6. Golino P, Rosolowsky M, Yao S-K, et al. Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. J Clin Invest 1990;86:1095-102.
7. Golino P, Ashton JH, McNatt J, et al. Simultaneous administration of thromboxane A2- and serotonin S2-receptor antagonists markedly enhances thrombolysis and prevents or delays reocclusion after tissue-type plasminogen activator in a canine model of coronary thrombosis. Circulation 1989;79: 911-9.
8. Coller BS, Peershke EI, Scudder LE, Sullivan CA. A murine monoclonal antibody that completely blocks binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins lib and/or Ilia. J Clin Invest 1983;72:325-38.
9. Yasuda T, Gold HK, Fallon JT, et al. Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with re-combinant tissue-type plasminogen activator in dogs. J Clin Invest 1988;81:1284-91.
10. Ruoslahti E, Perschbacher MD. New perspectives in cell adhesion: RGD and integrins. Science 1987;238:491-7.
11. Haskel EJ, Adams SP, Feigen LP, et al. Prevention of re-occluding platelet-rich thrombi in canine femoral arteries with a novel peptide antagonist of platelet glycoprotein IIb/IIIa receptors. Circulation 1989;80:1775-82.
12. Shebuski RJ, Stabilito IJ, Sitko GR, Polokoff MH. Acceleration of recombinant tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by the combination of heparin and the Arg-Gly-Asp-containing peptide bitistatin in a canine model of coronary thrombosis. Circulation 1990;82:169-77.
13. Yasuda T, Gold HK, Leinbach RC, et al. Kistrin, a polypeptide platelet GP IIb/IIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparation. Circulation 1991;83:1038-47.
14. Badimon L, Lassila R, Badimon JJ, Vallabhajosula S, Chesebro JH, Fuster V. Residual thrombus is more thrombogenic than severely damaged vessel wall. Circulation 1988;78:119.
15. Seitz R, Blanke H, Pratorius G, Strauer BE, Egbring R. Increased thrombin activity during thrombolysis. Thromb Haemost 1988:59:541-2.
16. Gulba DC, Daniel WG. Simon R. et al. Role of thrombolysis and thrombin in patients with acute coronary occlusion during percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1990:16:563-8.
17. Heras M, Chesebro JH, Webster MWI, et al. Hirudin, heparin, and placebo during deep arterial injury in the pig. Circulation 1990;82:1476-84.
18. Eidt JF, Allison P, Noble S, et al. Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury. J Clin Invest 1989;84:18-27.
19. Jang IK, Gold HK, Zisking AA, Leinbach RC, Fallon JT, Collen D. Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition. Circulation 1990;81:219-25.
20. Krupski WC, Bass A, Kelly AB, Marzec UM, Hanson SR, Harker LA. Heparin-resistant thrombus formation by endovascular stents in baboons. Interruption by a synthetic antithrombin. Circulation 1990;81:570-7.
21. Mellot MJ, Connolly TM, York SJ, Bush LR. Prevention of reocclusion by MCI-9038, a thrombin inhibitor, following t-PA-induced thrombolysis in a canine model of femoral arterial thrombosis. Thromb Haemost 1990;64:526-34.
22. Yasuda T, Gold HK, Yaoita H, et al. Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein Hb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation. J Am Coll Cardiol 1990;16:714-22.
23. Haskel EJ, Prager NA, Sobel BE, Abendschein DR. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion. Circulation 1991;83:1048-56.
24. Sitko GR, Ramjit DR, Stabilito II, Lehman D, Lynch JJ, Vlasuk GP. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with selective factor Xa inhibitor, tick anticoagulant peptide: comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis. Circulation 1992;85:805-15.
25. Jackson CV, Crowe VG, Frank JD, et al. Pharmacological assessment of the antithrombotic activity of the peptide thrombin inhibitor, D-methyl-phenylalanyl-prolyl-arginal (GYKI-14766), in a canine model of coronary artery thrombosis. J Pharmacol Exp Ther 1992;261:546-52.
26. Jackson CV, Crowe VG, Craft TJ, et al. Thrombolytic activity of a novel plasminogen activator, LY210825, compared with recombinant tissue-type plasminogen activator in a canine model of coronary artery thrombosis. Circulation 1990;82:930-40.
27. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin Ill-independent inhibitors. J Clin Invest 1990;86: 385-91.
28. Bajusz S, Szell E, Badgy D, et al. Highly active and selective anticoagulants: D-Phe-Pro-Arg-H, a free tripeptide aldehyde prone to spontaneous inactivation, and its stable N-methyl derivative, D-MePhe-Pro-Arg-H. J Med Chem 1990;33: 1729-35.
29. Mueller HS, Roberts R, Teichman SL, Sobel BE. Thrombolytic therapy in acute myocardial infarction: part II-rt-PA. Med Clin North Am 1989;73:387-407.
30. Levine SP, Wohl H. Human platelet factor 4; purification and characterization by affinity chromatography. J Biol Chem 1976;251:324-8.
31. Handin RI, Cohen HJ. Purification and binding properties of human platelet factor four. J Biol Chem 1976;251:4273-82.
32. Jakubowski JA, Maraganore JM. Inhibition of coagulation and thrombin-induced platelet activities by a synthetic dodecapeptide modeled on the carboxyterminus of hirudin. Blood 1990;75:399-406.
33. Hoog PJ, Jackson CM. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy. Proc Natl Acad Sci USA 1989;86:3619-23.
34. Kawano K, Ikeda Y, Handa M, et al. Enhancing effect by heparin on shear-induced platelet aggregation. Sem Thromb Haemost 1990;16:60-5.